Al­ler­gan bags an ear­ly-stage gene ther­a­py in $60M Ret­roSense buy­out

While Al­ler­gan’s ac­quis­i­tive CEO Brent Saun­ders was map­ping out a new com­mit­ment to shun preda­to­ry pric­ing, he si­mul­ta­ne­ous­ly threw in the lat­est in a se­ries …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER